Does TP53 mutation promote ovarian cancer metastasis to omentum by regulating lipid metabolism?

Medical Hypotheses

Volumn 81, Issue 4, 2013, Pages 515-520

  Hu, Jing ^a   Liu, Zhiqiang ^a   Wang, Xipeng ^a  

^a TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

FATTY ACID; FATTY ACID BINDING PROTEIN 4; GUANIDINOACETATE METHYLTRANSFERASE; INTERLEUKIN 8; PROTEIN P53; STEROL REGULATORY ELEMENT BINDING PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

ABDOMINAL FAT; ARTICLE; CANCER CELL; CHOLESTEROL SYNTHESIS; CYTOKINE PRODUCTION; EPITHELIAL MESENCHYMAL TRANSITION; FATTY ACID METABOLISM; FATTY ACID OXIDATION; GENE EXPRESSION; GENE MUTATION; LIPID METABOLISM; METASTASIS; OMENTUM; OVARY CANCER; REGULATORY MECHANISM; TUMOR MICROENVIRONMENT;

FATTY ACID-BINDING PROTEINS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GUANIDINOACETATE N-METHYLTRANSFERASE; HUMANS; INTERLEUKIN-8; LIPID METABOLISM; MUTATION; NEOPLASM METASTASIS; OMENTUM; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; STEROL REGULATORY ELEMENT BINDING PROTEINS; TRANSFORMING GROWTH FACTOR BETA; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84883767390     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2013.06.009     Document Type: Article

References (61)

1. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013, 63(1):11-30.
2. Coleman M.P., Forman D., Bryant H., et al. Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995-2007 (the International Cancer Benchmarking Partnership): an analysis of population-based cancer registry data. Lancet 2011, 377(9760):127-138.
3. McGuire W.P. Maintenance therapy for ovarian cancer: of Helsinki and Hippocrates. J Clin Oncol 2009, 27(28):4633-4634.
4. Seidman J.D., Kurman R.J. Pathology of ovarian carcinoma. Hematol Oncol Clin North Am 2003, 17(4):909-925. [vii].
5. Seidman J.D., Horkayne-Szakaly I., Haiba M., Boice C.R., Kurman R.J., Ronnett B.M. The histologic type and stage distribution of ovarian carcinomas of surface epithelial origin. Int J Gynecol Pathol 2004, 23(1):41-44.
6. Levine A.J., Oren M. The first 30years of p53: growing ever more complex. Nat Rev Cancer 2009, 9(10):749-758.
7. Goldstein I., Marcel V., Olivier M., Oren M., Rotter V., Hainaut P. Understanding wild-type and mutant p53 activities in human cancer: new landmarks on the way to targeted therapies. Cancer Gene Ther 2011, 18(1):2-11.
8. Cancer Genome Atlas Research Network Integrated genomic analyses of ovarian carcinoma. Nature 2011, 474(7353):609-615.
9. Ahmed A.A., Etemadmoghadam D., Temple J., et al. Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. J Pathol 2010, 221(1):49-56.
10. Bensaad K., Tsuruta A., Selak M.A., et al. TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell 2006, 126(1):107-120.
11. Suzuki S., Tanaka T., Poyurovsky M.V., et al. Phosphate-activated glutaminase (GLS2), a p53-inducible regulator of glutamine metabolism and reactive oxygen species. Proc Natl Acad Sci USA 2010, 107(16):7461-7466.
12. Matoba S., Kang J.G., Patino W.D., et al. P53 regulates mitochondrial respiration. Science 2006, 312(5780):1650-1653.
13. Kawauchi K., Araki K., Tobiume K., Tanaka N. P53 regulates glucose metabolism through an IKK-NF-kappaB pathway and inhibits cell transformation. Nat Cell Biol 2008, 10(5):611-618.
14. Hu W., Zhang C., Wu R., Sun Y., Levine A., Feng Z. Glutaminase 2, a novel p53 target gene regulating energy metabolism and antioxidant function. Proc Natl Acad Sci USA 2010, 107(16):7455-7460.
15. Goldstein I., Ezra O., Rivlin N., et al. P53, a novel regulator of lipid metabolism pathways. J Hepatol 2012, 56(3):656-662.
16. Soussi T., Béroud C. Assessing TP53 status in human tumours to evaluate clinical outcome. Nat Rev Cancer 2001, 1(3):233-240.
17. Brosh R., Rotter V. When mutants gain new powers: news from the mutant p53 field. Nat Rev Cancer 2009, 9(10):701-713.
18. Morton J.P., Timpson P., Karim S.A., et al. Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer. Proc Natl Acad Sci USA 2010, 107(1):246-251.
19. Jiang P., Du W., Wang X., et al. P53 regulates biosynthesis through direct inactivation of glucose-6-phosphate dehydrogenase. Nat Cell Biol 2011, 13(3):310-316.
20. Horton J.D., Goldstein J.L., Brown M.S. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest 2002, 109(9):1125-1131.
21. Wang X., Sato R., Brown M.S., Hua X., Goldstein J.L. SREBP-1, a membrane-bound transcription factor released by sterol-regulated proteolysis. Cell 1994, 77(1):53-62.
22. Yahagi N., Shimano H., Matsuzaka T., et al. P53 activation in adipocytes of obese mice. J Biol Chem 2003, 278(28):25395-25400.
23. Ide T., Brown-Endres L., Chu K., et al. GAMT, a p53-inducible modulator of apoptosis, is critical for the adaptive response to nutrient stress. Mol Cell 2009, 36(3):379-392.
24. Ide T., Chu K., Aaronson S.A., Lee S.W. GAMT joins the p53 network: branching into metabolism. Cell Cycle 2010, 9(9):1706-1710.
25. Swinnen J.V., Brusselmans K., Verhoeven G. Increased lipogenesis in cancer cells: new players, novel targets. Curr Opin Clin Nutr Metab Care 2006, 9(4):358-365.
26. Freed-Pastor W.A., Mizuno H., Zhao X., et al. Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway. Cell 2012, 148(1-2):244-258.
27. Gansler T.S., Hardman W., Hunt D.A., Schaffel S., Hennigar R.A. Increased expression of fatty acid synthase (OA-519) in ovarian neoplasms predicts shorter survival. Hum Pathol 1997, 28(6):686-692.
28. Zhou W., Han W.F., Landree L.E., et al. Fatty acid synthase inhibition activates AMP-activated protein kinase in SKOV3 human ovarian cancer cells. Cancer Res 2007, 67(7):2964-2971.
29. Matsuura M., Suzuki T., Suzuki M., Tanaka R., Ito E., Saito T. Statin-mediated reduction of osteopontin expression induces apoptosis and cell growth arrest in ovarian clear cell carcinoma. Oncol Rep 2011, 25(1):41-47.
30. Elmore R.G., Ioffe Y., Scoles D.R., Karlan B.Y., Li A.J. Impact of statin therapy on survival in epithelial ovarian cancer. Gynecol Oncol 2008, 111(1):102-105.
31. Polyak K., Weinberg R.A. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer 2009, 9(4):265-273.
32. Rhim A.D., Mirek E.T., Aiello N.M., et al. EMT and dissemination precede pancreatic tumor formation. Cell 2012, 148(1-2):349-361.
33. Feng X.H., Derynck R. Specificity and versatility in tgf-beta signaling through Smads. Annu Rev Cell Dev Biol 2005, 21:659-693.
34. Miyazawa K., Shinozaki M., Hara T., Furuya T., Miyazono K. Two major Smad pathways in TGF-beta superfamily signalling. Genes Cells 2002, 7(12):1191-1204.
35. Davies M., Robinson M., Smith E., Huntley S., Prime S., Paterson I. Induction of an epithelial to mesenchymal transition in human immortal and malignant keratinocytes by TGF-beta1 involves MAPK, Smad and AP-1 signalling pathways. J Cell Biochem 2005, 95(5):918-931.
36. Margetts P.J., Bonniaud P., Liu L., et al. Transient overexpression of TGF-{beta}1 induces epithelial mesenchymal transition in the rodent peritoneum. J Am Soc Nephrol 2005, 16(2):425-436.
37. Miettinen P.J., Ebner R., Lopez A.R., Derynck R. TGF-beta induced transdifferentiation of mammary epithelial cells to mesenchymal cells: involvement of type I receptors. J Cell Biol 1994, 127(6 Pt 2):2021-2036.
38. Schiller M., Javelaud D., Mauviel A. TGF-beta-induced SMAD signaling and gene regulation: consequences for extracellular matrix remodeling and wound healing. J Dermatol Sci 2004, 35(2):83-92.
39. Zavadil J., Böttinger E.P. TGF-beta and epithelial-to-mesenchymal transitions. Oncogene 2005, 24(37):5764-5774.
40. Adorno M., Cordenonsi M., Montagner M., et al. A Mutant-p53/Smad complex opposes p63 to empower TGFbeta-induced metastasis. Cell 2009, 137(1):87-98.
41. Shiota M., Izumi H., Onitsuka T., et al. Twist and p53 reciprocally regulate target genes via direct interaction. Oncogene 2008, 27(42):5543-5553.
42. Bolós V., Peinado H., Pérez-Moreno M.A., Fraga M.F., Esteller M., Cano A. The transcription factor Slug represses E-cadherin expression and induces epithelial to mesenchymal transitions: a comparison with Snail and E47 repressors. J Cell Sci 2003, 116(Pt 3):499-511.
43. Shih J.Y., Tsai M.F., Chang T.H., et al. Transcription repressor Slug promotes carcinoma invasion and predicts outcome of patients with lung adenocarcinoma. Clin Cancer Res 2005, 11(22):8070-8078.
44. Smit M.A., Peeper D.S. Deregulating EMT and senescence: double impact by a single twist. Cancer Cell 2008, 14(1):5-7.
45. Kogan-Sakin I., Tabach Y., Buganim Y., et al. Mutant p53(R175H) upregulates Twist1 expression and promotes epithelial-mesenchymal transition in immortalized prostate cells. Cell Death Differ 2011, 18(2):271-281.
46. Wang S.P., Wang W.L., Chang Y.L., et al. P53 controls cancer cell invasion by inducing the MDM2-mediated degradation of Slug. Nat Cell Biol 2009, 11(6):694-704.
47. Fuxe J., Vincent T. Garcia de Herreros A. Transcriptional crosstalk between TGF-β and stem cell pathways in tumor cell invasion: role of EMT promoting Smad complexes. Cell Cycle 2010, 9(12):2363-2374.
48. Gay L.J., Felding-Habermann B. Contribution of platelets to tumour metastasis. Nat Rev Cancer 2011, 11(2):123-134.
49. Stone R.L., Nick A.M., McNeish I.A., et al. Paraneoplastic thrombocytosis in ovarian cancer. N Engl J Med 2012, 366(7):610-618.
50. Labelle M., Begum S., Hynes R.O. Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis. Cancer Cell 2011, 20(5):576-590.
51. Bai Z.F., Tai Y., Li W., et al. Gankyrin activates IL-8 to promote hepatic metastasis of colorectal cancer. Cancer Res 2013, [Epub ahead of print].
52. Sterling J.A., Edwards J.R., Martin T.J., Mundy G.R. Advances in the biology of bone metastasis: how the skeleton affects tumor behavior. Bone 2011, 48(1):6-15.
53. Shahzad M.M., Arevalo J.M., Armaiz-Pena G.N., et al. Stress effects on FosB- and interleukin-8 (IL8)-driven ovarian cancer growth and metastasis. J Biol Chem 2010, 285(46):35462-35470.
54. Nieman K.M., Kenny H.A., Penicka C.V., et al. Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat Med 2011, 17(11):1498-1503.
55. Merritt W.M., Lin Y.G., Spannuth W.A., et al. Effect of interleukin-8 gene silencing with liposome-encapsulated small interfering RNA on ovarian cancer cell growth. J Natl Cancer Inst 2008, 100(5):359-372.
56. Furuhashi M., Hotamisligil G.S. Fatty acid-binding proteins: role in metabolic diseases and potential as drug targets. Nat Rev Drug Discov 2008, 7(6):489-503.
57. Hotamisligil G.S., Johnson R.S., Distel R.J., Ellis R., Papaioannou V.E., Spiegelman B.M. Uncoupling of obesity from insulin resistance through a targeted mutation in aP2, the adipocyte fatty acid binding protein. Science 1996, 274(5291):1377-1379.
58. Zimmerman A.W., Veerkamp J.H. New insights into the structure and function of fatty acid-binding proteins. Cell Mol Life Sci 2002, 59(7):1096-1116.
59. Sayed-Ahmed M.M., Al-Shabanah O.A., Hafez M.M., Aleisa A.M., Al-Rejaie S.S. Inhibition of gene expression of heart fatty acid binding protein and organic cation/carnitine transporter in doxorubicin cardiomyopathic rat model. Eur J Pharmacol 2010, 640(1-3):143-149.
60. Furuhashi M., Tuncman G., Görgün C.Z., et al. Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. Nature 2007, 447(7147):959-965.
61. Hertzel A.V., Hellberg K., Reynolds J.M., et al. Identification and characterization of a small molecule inhibitor of fatty acid binding proteins. J Med Chem 2009, 52(19):6024-6031.